

Data Sheet


WWW. UREIKO-CHEM. COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

Product Name :ZLY28 **Cat.No.** :URK-V2481

CAS No.

Target : Solubility :



Biological Activity

ZLY28 is an effective treatment for NASH, with many researchers finding it to be a highly promising drug candidate. As a dual regulator of FXR and FABP1, ZLY28 has the ability to improve the overall function of liver cells and reduce inflammation and fibrosis in the liver. Moreover, its oral activity makes it very convenient and non-invasive for patients.

Numerous scientific studies, clinical trials, and literature have been done to evaluate the efficacy of ZLY28. The findings have shown that ZLY28 has a high potential therapeutic effect and is a reliable treatment for NASH.

References

1. Ren Q, et al. Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease. J Med Chem. 2023;66(9):6082-6104

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!